The stock of Masimo Corporation (NASDAQ:MASI) reached all time high today, Nov, 24 and still has $64.57 target or 4.00% above today’s $62.09 share price. This indicates more upside for the $3.07 billion company. This technical setup was reported by Barchart.com. If the $64.57 PT is reached, the company will be worth $122.80M more.
Trading stocks at an all time highs is usually a winning strategy. An all time high points to a stock which has the most positive fundamentals ever. Even thought the pullback rate is high, if correct risk management is utilized, investors can trade very well such events. The stock increased 0.50% or $0.31 on November 23, hitting $62.09. About 229,396 shares traded hands. Masimo Corporation (NASDAQ:MASI) has risen 43.30% since April 22, 2016 and is uptrending. It has outperformed by 37.89% the S&P500.
Analysts await Masimo Corporation (NASDAQ:MASI) to report earnings on February, 28. They expect $0.51 earnings per share, up 240.00% or $0.36 from last year’s $0.15 per share. MASI’s profit will be $25.22M for 30.44 P/E if the $0.51 EPS becomes a reality. After $0.47 actual earnings per share reported by Masimo Corporation for the previous quarter, Wall Street now forecasts 8.51% EPS growth.
Masimo Corporation (NASDAQ:MASI) Ratings Coverage
Out of 3 analysts covering Masimo (NASDAQ:MASI), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Masimo has been the topic of 3 analyst reports since August 5, 2015 according to StockzIntelligence Inc. The stock of Masimo Corporation (NASDAQ:MASI) has “Outperform” rating given on Wednesday, January 6 by Raymond James. TH Capital maintained Masimo Corporation (NASDAQ:MASI) on Wednesday, August 5 with “Buy” rating.
According to Zacks Investment Research, “Masimo develops innovative monitoring technologies that significantly improve patient care — helping solve unsolvable problems. The company debuted Read-Through Motion and Low Perfusion pulse oximetry, known as SET, and with it substantially reduced false alarms and increased pulse oximetry’s ability to detect life-threatening events. Our Masimo SET platform has significantly addressed many of the previous technology limitations, has substantially contributed to improved patient outcomes and has been referred to by several industry sources as the gold standard in pulse oximetry. Masimo has introduced Masimo Rainbow SET Pulse CO-Oximetry, which, for the first time, noninvasively monitors the level of carbon monoxide and methemoglobin in the blood, allowing early detection and treatment of potentially life-threatening conditions. Masimo has the mission of Improving Patient Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications.”
Insitutional Activity: The institutional sentiment increased to 1.33 in Q2 2016. Its up 0.01, from 1.32 in 2016Q1. The ratio increased, as 14 funds sold all Masimo Corporation shares owned while 85 reduced positions. 52 funds bought stakes while 79 increased positions. They now own 38.69 million shares or 0.37% less from 38.84 million shares in 2016Q1.
Dupont Mngmt Corp has 23,254 shares for 0.03% of their US portfolio. Deutsche Financial Bank Ag last reported 341,454 shares in the company. Menta Ltd Limited Liability Company last reported 0.42% of its portfolio in the stock. Robeco Institutional Asset Mgmt Bv holds 0% of its portfolio in Masimo Corporation (NASDAQ:MASI) for 12,178 shares. The Switzerland-based Swiss National Bank has invested 0.01% in Masimo Corporation (NASDAQ:MASI). The Massachusetts-based Bogle Inv Ltd Partnership De has invested 0.89% in Masimo Corporation (NASDAQ:MASI). Dafna Capital Mngmt Llc last reported 0.42% of its portfolio in the stock. Grt Partners Limited Company last reported 13,346 shares in the company. Public Employees Retirement Association Of Colorado, a Colorado-based fund reported 12,633 shares. Invesco Ltd last reported 194,860 shares in the company. Thrivent Finance For Lutherans has 21,400 shares for 0.01% of their US portfolio. Credit Suisse Ag accumulated 0.01% or 104,584 shares. Cibc World Mkts Incorporated accumulated 0.02% or 75,307 shares. California State Teachers Retirement accumulated 0.01% or 85,800 shares. Panagora Asset Mgmt has 73,584 shares for 0.02% of their US portfolio.
Insider Transactions: Since May 25, 2016, the stock had 0 insider purchases, and 27 sales for $33.69 million net activity. $3.58M worth of Masimo Corporation (NASDAQ:MASI) was sold by Sampath Anand. Fishel Rick also sold $1.25 million worth of Masimo Corporation (NASDAQ:MASI) shares. FITCH SANFORD sold $119,623 worth of stock. $360,000 worth of shares were sold by Coleman Jon on Monday, November 7. Another trade for 40,000 shares valued at $1.98M was sold by de Raad Mark. 20,381 shares were sold by KIANI JOE E, worth $1.26 million. 30,000 Masimo Corporation (NASDAQ:MASI) shares with value of $1.82 million were sold by Lee Yongsam.
MASI Company Profile
Masimo Corporation, incorporated on May 7, 1996, is a medical technology firm that develops, makes and markets non-invasive patient monitoring products. The Company’s business is measure-through-motion and low-perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry. The Company’s product offerings include monitoring blood constituents with an optical signature, optical organ oximetry monitoring, electrical brain function monitoring, acoustic respiration monitoring and exhaled gas monitoring. In addition, the Company has developed the Root patient monitoring and connectivity platform, the Radical-7 bedside and portable patient monitor and the Radius-7 wearable wireless patient monitor. It has also developed the Patient SafetyNet remote patient surveillance monitoring system, which allows over 200 patients to be monitored simultaneously and remotely through a personal computer (PC) viewing station or by care providers through their pagers, voice-over-Internet Protocol (IP) phones or smartphones.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.